The European Commission has approved Tryngolza (olezarsen) for use in the European Union (EU) as an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS). The approval is based on positive data from the Phase 3 Balance study, in which olezarsen 80 mg significantly reduced fasting TG levels at six months, and was associated with a reduction in acute pancreatitis at week 53.
Topline CORE and CORE2 data show 85% pancreatitis reduction with olezarsen
Topline olezarsen data from the Phase 3 CORE and CORE2 trials in patients with severe hypertriglyceridaemia (sHTG) show significant placebo-adjusted mean reductions in fasting TG of up to 72% at six months, and a pre-specified analysis of pooled data from olezarsen and placebo groups in both studies show a statistically significant reduction in acute pancreatitis events of 85% (p=0.0002) at 12 months.
Using high dose EPA in patients with hypertriglyceridaemia
Recent data show that although elevated LDL-C may be well treated, hypertriglyceridaemia is still addressed less effectively. Professor Chris J Packard, Professor of Vascular Biochemistry, Glasgow, UK, reviews evidence on the use of high dose eicosapentaenoic acid (EPA) to lower triglyceride levels and reduce cardiovascular risk, stresses the importance of triglyceride testing, and discusses scenarios for adding high dose EPA or non-statin LDL-C lowering agents to optimised statin therapy.
New clues to link between postprandial plasma TG and CV and T2D risk
Biochemical and genomic results from a study of 21 healthy, non-obese individuals aged 18-40 years have shown that those with high post-prandial TG (HPTG) five hours after a high fat meal had significantly higher levels of plasma insulin and lipopolysaccharide-binding protein (LPB) than those with low post-prandial TG (LPTG), potentially putting them at higher risk of cardiovascular disease (CVD) and type 2 diabetes (T2D).
Maastricht Study shows increased HTG risk with steatotic liver disease
Genetically predisposed individuals have a substantially higher risk of hypertriglyceridaemia when they also have steatotic liver disease, according to results from the Maastricht Study, a population-based, prospective cohort analysis.
Topline Essence-TIMI 73b data support olezarsen in moderate hypertriglyceridaemia
Topline results from the Phase 3 Essence-TIMI 73b study provide encouraging evidence of the efficacy of olezarsen in patients with moderate hypertriglyceridaemia (fasting TG 150 mg/dL to <500 mg/dL) with or at risk of atherosclerotic cardiovascular disease (ASCVD).
